Genetic modifications to temperate Enterococcus faecalis phage  Ef11 that abolish the establishment of lysogeny and sensitivity to repressor, and increase host range and productivity of lytic infection

Eight-year (2002-2009) Summary of the Linezolid (Zyvox®Annual Appraisal of potency and Spectrum; ZAAPS) Program in European Countries

(2014) J.E. Ross et al.   JOURNAL OF CHEMOTHERAPY

Intensive care unit dissemination of multiple clones of linezolid-resistant Enterococcus faecalis and Enterococcus faecium

(2012) E. Ntokou et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Daptomycin Nonsusceptible Enterococci: An Emerging Challenge for Clinicians

(2010) T. Kelesidis et al.   CLINICAL INFECTIOUS DISEASES

The annotated complete DNA sequence of Enterococcus faecalis bacteriophage φEf11 and its comparison with all available phage and predicted prophage genomes

(2010) Roy H. Stevens et al.   FEMS MICROBIOLOGY LETTERS

Comparative Genomics and Transduction Potential of Enterococcus faecalis Temperate Bacteriophages

(2009) A. Yasmin et al.   JOURNAL OF BACTERIOLOGY

Bacteriophages induced from lysogenic root canal isolates ofEnterococcus faecalis

(2009) R. H. Stevens et al.   Oral microbiology and immunology

Daptomycin resistance in Enterococcus faecalis prosthetic valve endocarditis

(2008) A. I. Hidron et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY